@article{30af6bbf9b2944b7a3fef872c30af227,
title = "Intramyocardial Transplantation of Human iPS Cell–Derived Cardiac Spheroids Improves Cardiac Function in Heart Failure Animals",
abstract = "The severe shortage of donor hearts hampered the cardiac transplantation to patients with advanced heart failure. Therefore, cardiac regenerative therapies are eagerly awaited as a substitution. Human induced pluripotent stem cells (hiPSCs) are realistic cell source for regenerative cardiomyocytes. The hiPSC-derived cardiomyocytes are highly expected to help the recovery of heart. Avoidance of teratoma formation and large-scale culture of cardiomyocytes are definitely necessary for clinical setting. The combination of pure cardiac spheroids and gelatin hydrogel succeeded to recover reduced ejection fraction. The feasible transplantation strategy including transplantation device for regenerative cardiomyocytes are established in this study.",
keywords = "cardiac spheroids, cardiomyocyte, cell transplantation, heart failure, human iPS cells",
author = "Shinji Kawaguchi and Yusuke Soma and Kazuaki Nakajima and Hideaki Kanazawa and Shugo Tohyama and Ryota Tabei and Akinori Hirano and Noriko Handa and Yoshitake Yamada and Shigeo Okuda and Shuji Hishikawa and Takumi Teratani and Satoshi Kunita and Yoshikazu Kishino and Marina Okada and Sho Tanosaki and Shota Someya and Yuika Morita and Hidenori Tani and Yujiro Kawai and Masataka Yamazaki and Akira Ito and Rei Shibata and Toyoaki Murohara and Yasuhiko Tabata and Eiji Kobayashi and Hideyuki Shimizu and Keiichi Fukuda and Jun Fujita",
note = "Funding Information: This work was supported by the Highway Program for Realization of Regenerative Medicine (17bm054006h0007 [to Dr. Fukuda]) and the Research Project for Practical Applications of Regenerative Medicine (17bk010462h0001 [to Dr. Fukuda]) from the Japan Agency for Medical Research and Development, and a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology (nos. 15K09098 [to Dr. Kanazawa], 16K09507 [to Dr. Fujita], 19H03660 [to Dr. Fujita], 17H05067 [to Dr. Tohyama], 18K15903 [to Dr. Nakajima]). Drs. Kanazawa, Tohyama, Fukuda, and Fujita have patents related to this work. Drs. Tohyama, Shimizu, Kanazawa, Fukuda, and Fujita own equity in Heartseed, Inc. Dr. Tohyama is an advisor of Heartseed, Inc. Dr. Fukuda is a co-founder and CEO of Heartseed, Inc., and receives a salary from Heartseed, Inc. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Funding Information: The authors thank Miho Yamaguchi, Rei Ohno, Chihana Fujita, Sayaka Kanaami, Yoshiko Miyake, and Tomoko Haruna for technical assistance. They also thank the National BioResource Project - Rat for providing the rat strain, F344-Il2rgem7Kyo. The authors thank Astellas Pharma Inc. for the gift of tacrolimus. They also thank Profs. Hideyuki Okano (Department of Physiology, Keio University) and Masaya Nakamura (Department of Orthopaedic Surgery, Keio University) for providing the lentiviral vector (CSII-EF-dVenus-Luc2). Publisher Copyright: {\textcopyright} 2021 The Authors",
year = "2021",
month = mar,
doi = "10.1016/j.jacbts.2020.11.017",
language = "English",
volume = "6",
pages = "239--254",
journal = "JACC: Basic to Translational Science",
issn = "2452-302X",
publisher = "Elsevier Inc.",
number = "3",
}
